I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
2 Ergebnisse
1
Outcome of very high-risk patients treated by Sotrovimab fo..:
Martin-Blondel, Guillaume
;
Marcelin, Anne-Genevieve
;
Soulié, Cathia
...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jinf.2022.04.010. , 2022
Link:
https://hal.sorbonne-universite.fr/hal-03784773
2
Outcome of very high-risk patients treated by Sotrovimab fo..:
Martin-Blondel, Guillaume
;
Marcelin, Anne-Genevieve
;
Soulié, Cathia
...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jinf.2022.04.010. , 2022
Link:
https://hal.sorbonne-universite.fr/hal-03784773
RT Journal T1
Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)
UL https://suche.suub.uni-bremen.de/peid=base-ftutoulouse3hal:oai:HAL:hal-03784773v1&Exemplar=1&LAN=DE A1 Martin-Blondel, Guillaume A1 Marcelin, Anne-Genevieve A1 Soulié, Cathia A1 Kaisaridi, Sofia A1 Lusivika-Nzinga, Clovis A1 Dorival, Céline A1 Nailler, Laura A1 Boston, Anaïs A1 Melenotte, Cléa A1 Gaube, Géraldine A1 Choquet, Christophe A1 Liblau, Roland A1 Carrat, Fabrice A1 Yordanov, Youri PB HAL CCSD; WB Saunders YR 2022 K1 Omicron K1 SARS-CoV-2 K1 Sotrovimab K1 MESH: Antibodies K1 Monoclonal K1 Humanized K1 Neutralizing K1 MESH: COVID-19 K1 MESH: Humans K1 MESH: Prospective Studies K1 MESH: SARS-CoV-2 K1 [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie JF info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jinf.2022.04.010 LK http://dx.doi.org/https://hal.sorbonne-universite.fr/hal-03784773 DO https://hal.sorbonne-universite.fr/hal-03784773 SF ELIB - SuUB Bremen RT Journal T1
Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)
UL https://suche.suub.uni-bremen.de/peid=base-ftutoulouse3hal:oai:HAL:hal-03784773v1&Exemplar=1&LAN=DE A1 Martin-Blondel, Guillaume A1 Marcelin, Anne-Genevieve A1 Soulié, Cathia A1 Kaisaridi, Sofia A1 Lusivika-Nzinga, Clovis A1 Dorival, Céline A1 Nailler, Laura A1 Boston, Anaïs A1 Melenotte, Cléa A1 Gaube, Géraldine A1 Choquet, Christophe A1 Liblau, Roland A1 Carrat, Fabrice A1 Yordanov, Youri PB HAL CCSD; WB Saunders YR 2022 K1 Omicron K1 SARS-CoV-2 K1 Sotrovimab K1 MESH: Antibodies K1 Monoclonal K1 Humanized K1 Neutralizing K1 MESH: COVID-19 K1 MESH: Humans K1 MESH: Prospective Studies K1 MESH: SARS-CoV-2 K1 [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie JF info:eu-repo/semantics/altIdentifier/doi/10.1016/j.jinf.2022.04.010 LK http://dx.doi.org/https://hal.sorbonne-universite.fr/hal-03784773 DO https://hal.sorbonne-universite.fr/hal-03784773 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)